Executive Control Training for Adolescents With ADHD: A Randomized Controlled Effectiveness Trial
NCT05874791, Not applicable, Active not recruiting, Sykehuset Innlandet HF
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Executive Control Training for Adolescents With ADHD: A Randomized Controlled Effectiveness Trial | ClinicalTrials.gov |
| NCT number | NCT05874791 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Sykehuset Innlandet HF | ClinicalTrials.gov |
| Conditions | Attention Deficit Hyperactivity Disorder, Executive Dysfunction | ClinicalTrials.gov |
| Interventions | Goal Management training | ClinicalTrials.gov |
| First posted | 2023-05-25 | ClinicalTrials.gov |
| Last updated | 2025-05-28 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Parent-Reported Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, after 12 months, and after 24 months). | Rating inventory assessing executive function in daily life. Higher scores indicate greater executive dysfunction. The total score ranges from 86 - 258. | ClinicalTrials.gov |
| Secondary | Change in Self-Reported Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, after 12 months, and after 24 months). | Rating inventory assessing executive function in daily life. Higher scores indicate greater executive dysfunction. The total score ranges from 80 - 240. | ClinicalTrials.gov |
| Secondary | Change in Teacher-Reported Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Rating inventory assessing executive function in daily life. Higher scores indicate greater executive dysfunction. The total score ranges from 86 - 258. | ClinicalTrials.gov |
| Secondary | Change in Attention Span task from Cognitive Assessment at Bedside for IPad (CABPad). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Performance-based Executive functioning tests: To assess simple attention span. The scoring is based on the number of objects remembered. More objects indicate higher attention span. | ClinicalTrials.gov |
| Secondary | Change in Working Memory task from Cognitive Assessment at Bedside for IPad (CABPad). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Performance-based Executive functioning test: To assess working memory. The scoring is based on the number of objects remembered. More objects indicate a better working memory. | ClinicalTrials.gov |
| Secondary | Change in Arrow Stroop task from Cognitive Assessment at Bedside for IPad (CABPad). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Performance-based Executive functioning test: To investigate executive control of attention, more specifically cognitive impulse control. Scoring is based on reaction time and the number of incorrect/correct responses. | ClinicalTrials.gov |
| Secondary | Change in Symbol Digit Coding (Mental and Visuo-Motor Speed) task from Cognitive Assessment at Bedside for IPad (CABPad). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Performance-based Executive functioning test: To investigate mental and visuo-motor speed. Scoring is based on reaction time and the number of incorrect/correct responses. | ClinicalTrials.gov |
| Secondary | Change in Parent-Reported Achenbach System of Empirically Based Assessment (ASEBA). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, and after 24 months). | Assessment rating adaptive and maladaptive functioning. Higher scores indicate greater difficulty. The total score ranges from 0 - 224. | ClinicalTrials.gov |
| Secondary | Change in Self-Reported Achenbach System of Empirically Based Assessment (ASEBA). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, and after 24 months). | Assessment rating adaptive and maladaptive functioning. Higher scores indicate greater difficulty. The total score ranges from 0 - 224. | ClinicalTrials.gov |
| Secondary | Change in Parent-Reported Weiss Functional Impairment Rating Scale (WFIRS-P). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, and after 24 months). | Rating inventory that evaluates the extent to which an individual's ability to function is impaired. The 50-item scale uses a Likert scale, such that any item rating 2 or 3 is clinically impaired. The total score ranges from 0 - 150. | ClinicalTrials.gov |
| Secondary | Change in Parent-Reported ADHD Rating scale (ADHD-RS-IV Home). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, and after 24 months). | Rating inventory that detects ADHD symptoms in children and adolescents reported by parents. The 18-item scale generates a total score between 0 - 54, where the higher score indicates greater difficulty. | ClinicalTrials.gov |
| Secondary | Change in Teacher-Reported ADHD Rating scale (ADHD-RS-IV School). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Rating inventory that detects ADHD symptoms in children and adolescents. The 18-item scale generates a total score between 0 - 54, where the higher score indicates greater difficulty. | ClinicalTrials.gov |
| Secondary | Change in Parent-Rated Pediatric Quality of Life Inventory (PedsQL). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, and after 24 months). | Measurement of health-related quality of life. The 23-item scale generates a total score between 0-100, where 100 points indicate optimal quality of life. | ClinicalTrials.gov |
| Secondary | Change in Self-Rated Pediatric Quality of Life Inventory (PedsQL). | Change from Baseline up to 24 months (Assessed at Baseline, after 12 weeks, and after 24 months). | Measurement of health-related quality of life.The 23-items scale generates a total score between 0-100, where 100 points indicate optimal quality of life. | ClinicalTrials.gov |
| Secondary | Change in Goal Attainment Scaling (GAS). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Method of rating performance based on a criterion-referenced scale with defined anchor points. If the patient achieves the expected level, this is scored at 0. If they achieve a better than expected outcome this is scored at: +1 (somewhat better), +2 (much better). If they achieve a worse than expected outcome this is scored at: -1 (somewhat worse), or -2 (much worse). The patient and the clinician decide this score together. | ClinicalTrials.gov |
| Secondary | Change in Children's Global Assessment Scale (CGAS). | Change from Baseline up to 12 weeks (Assessed at Baseline, and after 12 weeks). | Measure of a child's or adolescent's psychosocial functioning on a scale from 1 (lowest functioning) to 100 (superior functioning in all areas). Rated by an independent observer. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)